BGB-283 ide Rb3 Smiles: CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21

Smiles: CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21

dose-dependent accumulation of Chk1 pS345

and SLIGRL-NH2 is a PAR-2-activating peptide

Vercirnon (GSK1605786A) is an orally bioavailable

1'-biphenyl]-2-carboxylic acid

BGB-283 ide Rb3 Smiles: CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21BGB 283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB 283 potently inhibits BRafV600E activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRafV600E and EGFR mutation amplification. In BRafV600E colorectal cancer cell lines, BGB 283 effectively inhibits